During the last session, Kyverna Therapeutics Inc (NASDAQ:KYTX)’s traded shares were 0.82 million, with the beta value of the company hitting 2.13. At the end of the trading day, the stock’s price was $2.00, reflecting an intraday loss of -15.07% or -$0.36. The 52-week high for the KYTX share is $25.84, that puts it down -1192.0 from that peak though still a striking -10.0% loss since the share price plummeted to a 52-week low of $2.20. The company’s market capitalization is $86.34M, and the average intraday trading volume over the past 10 days was 0.36 million shares, and the average trade volume was 346.69K shares over the past three months.
Kyverna Therapeutics Inc (KYTX) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 1.00. KYTX has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 0 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.04.
Kyverna Therapeutics Inc (NASDAQ:KYTX) trade information
Kyverna Therapeutics Inc (KYTX) registered a -15.07% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -15.07% in intraday trading to $2.00, hitting a weekly high. The stock’s 5-day price performance is -15.97%, and it has moved by -28.57% in 30 days. Based on these gigs, the overall price performance for the year is -91.95%. The short interest in Kyverna Therapeutics Inc (NASDAQ:KYTX) is 2.87 million shares and it means that shorts have 10.85 day(s) to cover.
While earnings are projected to return -23.52% in 2025, the next five years will return -10.04% per annum.
KYTX Dividends
Kyverna Therapeutics Inc is due to release its next quarterly earnings on 2025-Mar-26. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Kyverna Therapeutics Inc (NASDAQ:KYTX)’s Major holders
Kyverna Therapeutics Inc insiders own 1.22% of total outstanding shares while institutional holders control 85.13%, with the float percentage being 86.18%. VIDA VENTURES ADVISORS, LLC is the largest shareholder of the company, while 128.0 institutions own stock in it. As of 2024-06-30, the company held over 4.52 million shares (or 10.4901% of all shares), a total value of $33.93 million in shares.
The next largest institutional holding, with 3.37 million shares, is of BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC’s that is approximately 7.8106% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $25.26 million.
Also, the Mutual Funds coming in first place with the largest holdings of Kyverna Therapeutics Inc (KYTX) shares are JPMorgan Trust II-JPMorgan Small Cap Growth Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on Dec 31, 2024 indicates that JPMorgan Trust II-JPMorgan Small Cap Growth Fund owns about 1.0 shares. This amounts to just over 2.32 percent of the company’s overall shares, with a $2.01 million market value. The same data shows that the other fund manager holds slightly less at 806.42, or about 1.87% of the stock, which is worth about $1.61 million.
